

# Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé foci, Mali

Housseini Dolo<sup>1,6\*</sup>, Yaya I. Coulibaly<sup>1,2</sup>, Moussa Sow<sup>3</sup>, Massitan Dembélé<sup>4</sup>, Salif S. Doumbia<sup>1</sup>, Siaka Y. Coulibaly<sup>1</sup>, Moussa B. Sangare<sup>1</sup>, Ilo Dicko<sup>1</sup>, Abdallah A. Diallo<sup>1</sup>, Lamine Soumaoro<sup>1</sup>, Michel E. Coulibaly<sup>1</sup>, Dansine Diarra<sup>5</sup>, Robert Colebunders<sup>6</sup>, Thomas B. Nutman<sup>7</sup>, Martin Walker<sup>8\*</sup>, Maria-Gloria Basáñez<sup>9\*</sup>

<sup>1</sup> Lymphatic Filariasis Research Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali

<sup>2</sup> Centre National d'Appui à la lutte contre la Maladie (CNAM), Bamako, Mali

<sup>3</sup> Programme National de Lutte contre l'Onchocercose, Bamako, Mali

<sup>4</sup> Programme National d'Élimination de la Filariose Lymphatique, Bamako, Mali

<sup>5</sup> Faculty of Geography and History, Bamako, Mali

<sup>6</sup> Global Health Institute, University of Antwerp, Antwerp, Belgium

<sup>7</sup> Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

<sup>8</sup> Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research, Royal Veterinary College, Hatfield, UK

<sup>9</sup> Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, MRC Centre for Global Infectious Disease Analysis, Imperial College London, UK

\* contributed equally to this work.

Correspondence to:

Dr Housseini Dolo

Lymphatic Filariasis Research Unit

International Center of Excellence in Research (ICER Mali)

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

Faculté de Médecine et d'Odontostomatologie (FMOS)

BP 1805 Bamako

Mali

Mobile: + 223 76 28 92 39

hdolo@icermali.org

**Summary:** Ov16–Wb123 seroprevalence was measured in children  $\leq 10$  year-old to evaluate onchocerciasis and lymphatic filariasis elimination in two co-endemic foci (Bakoye and Falémé) in Mali under long-term ivermectin treatment, which stopped in 2016. These goals seem to have been achieved.

## Abstract

**Background.** In Mali, ivermectin-based onchocerciasis elimination from the Bakoye and Falémé foci, reported in 2009–2012, was a beacon leading to policy shifting from morbidity control to elimination of transmission (EOT). These foci are also endemic for lymphatic filariasis (LF). In 2007–2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24–25 years of treatment to evaluate if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.

**Methods.** The SD Bioline Onchocerciasis/LF IgG4 biphase rapid diagnostic test (RDT) was used in 2,186 children aged 3–10 years in 13 villages (plus two hamlets) in Bakoye, and 2,270 children in 15 villages (plus one hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in three historically hyperendemic villages, testing 1,867 individuals aged 3–78 years.

**Results.** In Bakoye, IgG4 seropositivity was 0.27% (95%CI=0.13–0.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was, respectively, 0.04% (95%CI=0.01–0.25%) and 0.09% (95%CI=0.02–0.32%). Ov16-seropositive children were from historically meso- and hyperendemic villages. Ov16 positivity was <2% in those ≤14 years, increasing to 16% in those ≥40 years. Wb123 seropositivity was <2% in those ≤39 years, reaching 3% in those ≥40 years.

**Conclusions.** Notwithstanding uncertainty in the biphase RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé appears consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip PCR tested and followed up.

**Key words:** onchocerciasis, lymphatic filariasis, serological monitoring, elimination, Mali

## Abbreviations

APOC: African Programme for Onchocerciasis Control; CDTI: community-directed treatment with ivermectin; CFA: circulating filarial antigen; CMFL: community microfilarial load; ELISA: enzyme-linked immunosorbent assay; EOT: elimination of transmission; EPHP: elimination as a public health problem; FMPOS: Faculty of Medicine, Pharmacy and Odontostomatology; FTS: filariasis test strip; GPELF: Global Programme to Eliminate Lymphatic Filariasis; ICT: immunochromatographic card test; IgG4: immunoglobulin G4; LF: lymphatic filariasis; MDA: mass drug administration; mf: microfilarial; mff: microfilariae; OCP: Onchocerciasis Control Programme in West Africa; PCR: polymerase chain reaction; RDT: rapid diagnostic test; spp: species; ss: skin snip; TAS: transmission assessment survey; USTTB: University of Sciences, Techniques and Technologies of Bamako; WHO: World Health Organization; 95% CI: ninety five percent confidence interval.

Onchocerciasis and lymphatic filariasis (LF) are endemic in Mali [1] but large-scale interventions have progressed towards elimination of transmission (EOT) for onchocerciasis and elimination as a public health problem (EHP) for LF. The Onchocerciasis Control Programme in West Africa (OCP) began vector control in Mali in 1977, identifying and larviciding *Simulium* (blackfly) breeding sites [2]. Some endemic parts of Mali were included in the OCP western extension, with ivermectin mass drug administration (MDA) starting in 1987. MDA was initially delivered by mobile teams and later by community-directed treatment with ivermectin (CDTI) assisted by the African Programme for Onchocerciasis Control (APOC) [3]. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) started in Mali in 2004, supporting ivermectin and albendazole distribution [1].

In 2010, APOC launched a conceptual and operational framework for onchocerciasis elimination with ivermectin treatment [4], spurred by promising findings in foci of Mali and Senegal using this strategy. In 2012, following the World Health Organization (WHO) roadmap on neglected tropical diseases [5], the target for onchocerciasis changed from morbidity control to EOT, contrasting with the LF goal of EHP [6].

Mali became one of the first African countries to demonstrate the principle of onchocerciasis elimination by ivermectin MDA as the sole intervention when elimination was documented in the Bakoye and Falémé foci, in 2009 and 2012 [7,8], following 15 (Bakoye) and 16 (Falémé) years of annual treatment. Treatment duration corresponds to first–last year when all first-line villages were treated, 1992–2006 (Bakoye) and 1991–2006 (Falémé) [7]. Because the LF programme started in 2007 in the same river basins, ivermectin distribution continued *de facto* for 9 years after 2006 (LF MDA stopped in 2016), bringing treatment duration to 24–25 years. Since 2011, a bednet distribution programme for malaria (which would also impact *Anopheles*-transmitted LF [9], the type occurring in Mali) was implemented.

For onchocerciasis, a threshold of <0.1% seropositivity (by IgG4 ELISA) to the *Onchocerca volvulus* Ov16 antigen in children aged <10 years is currently recommended by the WHO for

stopping ivermectin MDA [10]. For *Anopheles*-transmitted LF, the WHO guidelines recommend a threshold of <2% seropositivity to *Wuchereria bancrofti* circulating filarial antigen (CFA) with the filariasis test strip (FTS) (which replaced the immunochromatographic card test, ICT) in 6–7-year olds before ivermectin plus albendazole MDA may be stopped [11].

LF transmission assessment surveys (TAS) were conducted in 2016 and treatment stopped because all the health districts of the two foci passed the TAS using FTS, i.e. *W. bancrofti* antigenemia prevalence after 9 years of treatment was <2% at health district level [12], where sampling followed a community-based (household) design according to the WHO TAS protocol [11].

Documenting onchocerciasis elimination in Bakoye and Falémé was based on skin snip microscopy for detection and quantification of *O. volvulus* microfilaridermia, and PCR-based pool screening of blackfly samples for detection of infective, L3 larvae [7,8]. These data, alongside historical infection trends and treatment coverage information were later modelled using EPIONCHO and ONCHOSIM to estimate the risk of resurgence in Bakoye and the neighbouring River Gambia focus in Senegal [13] (data from Falémé were not available). Both models captured adequately the temporal prevalence trends and suggested a very low risk of resurgence in Bakoye, although EPIONCHO indicated a more substantive risk, particularly in historically hyperendemic communities [13]. Since the publication in 2016 of the World Health Organization (WHO) guidelines for stopping MDA and verifying onchocerciasis elimination [10], serological evaluation has become an important tool for transmission assessment.

Here, we use a rapid diagnostic test [14,15] to assess onchocerciasis and LF seroprevalence in the Bakoye and Falémé foci, 10 years after the first evidence of onchocerciasis elimination in these foci [7] and 3 years after passing TAS for LF in an onchocerciasis–LF co-endemic area in Mali.

## METHODS

### Ethical Approval

The study protocol (no. 2017/199/CE/FMPOS) was approved by the Ethical Committee of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Faculty of Medicine, Pharmacy and Odontostomatology (FMPOS). The objectives, procedure and methodology were explained to village elders and residents, and informed consent was obtained from parents/guardians of children and participants aged  $\geq 18$  years.

### Study Sites and Baseline Infection Indicators

The study was conducted between November 2017 and January 2018 in the Bakoye and Falémé former onchocerciasis foci [7,8]. In Bakoye, 13 villages (plus two hamlets) were studied, which had had a baseline *O. volvulus* microfilarial (mf) prevalence of 31%–70%. In Falémé, 15 villages (plus one hamlet) were studied, whose baseline mf prevalence had been 20%–57%. Figure 1 shows the locations of the foci and study villages in Mali. Tables 1 and 2 summarize, for Bakoye and Falémé respectively, pre-control parasitological data (mf prevalence and community microfilarial load (CMFL)). LF was endemic in the health district of Kita (Bakoye) and Kéniéba (Falémé) with a baseline antigenemia prevalence (in those  $\geq 15$  years) of 8.61% (13/151; 95% CI = 5.1–14.2%) using ICT to detect CFA in 2004 [12]. Supplementary Material provides further description of the study sites and onchocerciasis temporal trends under MDA.



**Figure 1****Table 1, Table 2****Study Populations**

Serum samples were collected from children aged 3–10 years borne/resident in Bakoye and Falémé in December 2017. In January 2018, and because modelling [13] had suggested a potential risk of resurgence in previously hyperendemic villages in Bakoye, serosurveys were also performed in the remaining (long-term resident) population (aged 11–78 years) in Kantila, Nioumala and Galé, which had had mf prevalences above 60% (Table 1). This was deemed not necessary in villages of lower baseline endemicity in both the Bakoye and Falémé foci.

**Serology Test**

The SD Bioline Onchocerciasis/LF IgG4 biplex rapid diagnostic test (RDT) [14,15] was used at the point-of-care as recommended by the manufacturer (SD Diagnostics, Korea). The test result was read after 30 minutes.

**Sample Sizes**

Sample sizes were calculated based on updated census data obtained in 2016–2017, provided by the Kita and Kéniéba health districts. It was estimated that the 3–10-year olds comprised approximately 22% of the population based on empirical data from onchocerciasis-endemic communities in Africa used to inform EPIONCHO's demographic structure [19], in agreement with the OCP reference population [16]. The proportional representation of different age groups in the three historically hyperendemic communities in the Bakoye focus was calculated in an analogous manner.

The study was powered on the basis of our *a priori* expectation that onchocerciasis EOT had taken place in Bakoye and Falémé since the last rounds of CDTI for onchocerciasis were undertaken in 2006–2007 [7,8] and for a further 9 years for LF. Therefore, the ‘true’ underlying seroprevalence in 3–10-year olds would be 0%. We further assumed that the specificity of the RDT was approximately 97.5% [14,15] and, therefore, we calculated sample sizes required to measure an RDT seroprevalence of 2.5% with a  $\pm 0.5\%$  precision. This yielded, for the first phase of the study, sample sizes of 3,508 in Bakoye and of 2,739 in Falémé. According to [10], a sample size of 2,000 children is needed to detect an Ov16 seroprevalence  $<0.1\%$  (upper 95% confidence limit).

For the second phase (all-age serosurvey) of the study, sample sizes for all other age groups ( $\geq 11$  years) in the three selected historically hyperendemic communities in Bakoye were based on estimating 50% seroprevalence (by RDT) with a precision of  $\pm 5\%$ . The value of 50% provided the most conservative sample size estimate of 1,257. In all cases, sample size calculations included a finite population size correction (i.e. sampling without replacement).

## Data Analysis

The standardized mf prevalence at baseline reported in Tables 1 and 2 are accompanied by 95% confidence intervals (95% CIs) calculated according to Wilson score interval [17]. Point seroprevalence estimates and associated 95% CIs were calculated using the same method by focus, village, and age group.

## RESULTS

### Study Population Characteristics

In the Bakoye focus, 2,186 children (aged 3–10 years) were tested for Ov16 and Wb123 IgG4 positivity (62% of the target sample size). The median age was 7 years and 53.6% were boys. For the three villages in which all-age serological surveys were conducted, 825 individuals aged  $\leq 10$  years and 1,042 individuals (aged  $\geq 11$  years) were tested (93% of the target); of the latter, the median age was 19 years, and 47.6% were men. In the Falémé focus, 2,270 children aged 3–10 years were included in the study (83% of the target). Village-level sample sizes for Bakoye and Falémé are given in Supplementary Material, Table S1. The median age was 6 years, and 51.9% were boys. Table 3 describes the population tested.

**Table 3**

### Onchocerciasis Mf Prevalence and CMFL Trends in Bakoye and Falémé

Figures 2 and 3 depict the decrease in mf prevalence and CMFL for the two foci, respectively, during 15–16 years of annual ivermectin MDA [7]. In Bakoye, levels of initial endemicity were higher than in Falémé. By 2010 (the last skin snip-based parasitological evaluation following the last ivermectin MDA round for onchocerciasis in 2006), most reported values were zero in both foci, with 95% CIs reflecting uncertainty due to sampling.

**Figure 2, Figure 3**

### Ov16 and Wb123 Seroprevalence Among Children in Bakoye and Falémé

In Bakoye, 6/2,186 children aged 3–10 years were positive for Ov16 IgG4 (0.27%, 95% CI = 0.13–0.60%), and 6 children were also positive for Wb123 IgG4 antibodies (same prevalence and 95% CIs but not necessarily the same children). The children who were

Ov16-positive were from the initially mesoendemic village of Badougou (a girl aged 10 years), the hyperendemic village of Kibi (a boy, aged 10, who was also positive for Wb123), and the highly hyperendemic village of Galé, where four children were seropositive (one girl aged 4 and another aged 8, positive for Ov16 only, plus one boy aged 7 and a girl aged 10, positive for both Ov16 and Wb123). The children who were only positive for Wb123 came from the villages of Kokounkoutouba (a boy aged 3), Kantila (a girl aged 9), and Galé (a boy aged 4). Supplementary Material, Table S1 presents Ov16 and Wb123 seropositivity per village in Bakoye.

In Falémé, Ov16 positivity was 1/2,270 (0.04%, 95%CI = 0.01–0.25%) in the 3–10-year-olds, the positive child originating from the mesoendemic community of Sely (one boy aged 7). Wb123 seropositivity was 2/2,270 (0.09%, 95%CI = 0.02–0.32%), the positive children being from the villages of Madina-Mandinga (a girl aged 7) and Mahinamine (a boy aged 10). Supplementary Material, Table S2 presents Ov16 and Wb123 seropositivity per village in Falémé.

### **Age-Specific Seroprevalence of Ov16 and Wb123 in Bakoye**

In the 3 historically hyperendemic villages selected for full age-range serological sampling, Ov16 IgG4 antibodies were detected in all 3 villages. Overall seroprevalence estimates (for individuals aged 3–78 years) were: 0.63% (95% CI = 0.17–2.26%) in Kantila (2 positives/319 tested); 7.0% (95% CI = 4.22–11.41%) in Nioumala (14 positives/200 tested), and 2.97% (95% CI = 2.19–4.02%) in Galé (40 positives/1,348 tested).

Wb123 IgG4 antibodies were also detected in all 3 villages. Overall seroprevalence estimates (for individuals aged 3–78 years) were: 0.31% (95% CI = 0.06–1.75%) in Kantila (1 positive/319 tested); 1.0% (95% CI = 0.27–3.57%) in Nioumala (2 positives/200 tested), and 1.19% (95% CI = 0.73–1.92%) in Galé (16 positives/1,348 tested). Figure 4 presents the age profiles of Ov16 and Wb123 seropositivity in the three villages combined.

Supplementary Material, Table S3 presents the results of Ov16 and Wb123 serology by age group in each of the three villages.

#### **Figure 4**

## **DISCUSSION**

The proof-of-principle onchocerciasis elimination from the Bakoye, Falémé and River Gambia foci in Mali and Senegal [7,8] provided seminal evidence that elimination in Africa could be achieved using ivermectin alone. This was pivotal in driving change in the WHO/APOC onchocerciasis goals from control to elimination [4]. Elimination was assessed based on epidemiological (skin snipping to detect/enumerate microfilariae) and entomological (PCR to detect *O. volvulus* L3 larvae in blackflies) evidence [7,8]. Since 2016, the WHO has advocated more stringent serological criteria for the safe stopping of MDA. These include the (statistically significant) demonstration of an Ov16 (by IgG4 ELISA) seroprevalence of <0.1% in children aged <10 years as measured [10]. For bancroftian (*Anopheles*-transmitted) LF, the FTS test is recommended for TAS and post-elimination surveillance, with a threshold of <2% [11]. The serological data presented here were obtained using the SD Bioline Onchocerciasis/LF IgG4 RDT test and so cannot be used for direct comparison with recommended thresholds indicative of elimination. However, these data do provide important empirical information on filariases transmission status in Mali.

Robust interpretation of serological data critically depends on the assay's diagnostic performance. The SD Bioline biplex test has a (manufacturer)-reported sensitivity of 92–98% for onchocerciasis and 81–95% for LF. Specificity estimates are, respectively, 97–100% and 96–99% [20]. Notwithstanding uncertainty in the field performance of the biplex RDT [14,15,21]—and the need for field-based studies to confirm the utility of the test for verification of elimination [22,23]—the Ov16 seroprevalence of 0.27% and 0.04% in children aged 3–10 years in, respectively, Bakoye and Falémé is broadly consistent with EOT. The

Wb123 seroprevalence of 0.27% in Bakoye and 0.09% in Falémé is also likely consistent with EPHP for LF, although there is no operational guidance on the interpretation of Wb123 serology in the context of LF transmission (but see [21]). Therefore, at the focus level and as of 2017–2018, we find no substantive evidence of onchocerciasis or LF resurgence since MDA cessation in 2016. However, the few Ov16 seropositive children identified here should be PCR-tested on skin snips to distinguish between parasite exposure and infection; if found negative, they could be omitted from the seroprevalence calculation but re-examined 1–1.5 years later to determine if they have become patent and should be treated [10].

The serological results in Bakoye contribute to validate previous modelling projections, indicating sustained elimination when EPIONCHO was fitted to the entire longitudinal data series (Fig. 3c of [13]). By contrast, likely resurgence was predicted by EPIONCHO (but not ONCHOSIM) in the neighbouring and more highly endemic River Gambia focus in Senegal (which was treated biannually) (Fig. 3g of [13]). Indeed, ivermectin MDA was resumed by the Senegalese National Onchocerciasis Control Program in the River Gambia focus in 2013 [24]. In 2014, an Ov16/Wb123 serological evaluation (using Luminex® multiplex-bead assay) across three river basins of the Kédougou Region (containing areas and some communities of [7,8]), found an Ov16 seroprevalence of 2.5% (7/279) in <10-year olds, including three positives in the River Gambia focus and four positives in the Senegalese part of the Falémé focus [24]. It is unclear whether these children were found in the same communities previously reported free of onchocerciasis transmission [7,8], but concerns were raised that transmission had either not been interrupted or had resurged [24]. All-age Ov16 serological profiles in the Bakoye focus of Mali [this work] are compared with those of the Kédougou Region of Senegal [24] in Supplementary Material Figure S1. Resurgence of onchocerciasis has been reported elsewhere in West Africa [25,26] highlighting the importance of robust epidemiological and entomological surveillance following cessation of interventions [27].

The three villages in Bakoye and one in Falémé that had children aged  $\leq 10$  years who were Ov16 IgG4 antibody positive were meso- or hyperendemic at baseline. The village of Galé—one of the largest and most hyperendemic villages before MDA (Figure 2)—had four seropositive (out of six in Bakoye) children (0.6%, Supplementary Material, Table S1). Although, arguably, these may all be false positives, variation in seropositivity among villages highlights the importance of spatial scale when designing monitoring, evaluation and surveillance sampling protocols. There currently exists no explicit guidance on how onchocerciasis elimination surveys should be implemented, nor on the appropriate spatial unit. For LF, an online survey-design tool can be used for school-based or community-based cluster randomised surveys within ‘evaluation units’ [11]. More guidance is needed on how best to implement onchocerciasis serological (and entomological) surveys. Spatially-explicit protocols, which have been developed for onchocerciasis elimination mapping (to identify previously untreated hypoendemic areas) [21] may prove useful.

The certainty of evidence indicative of onchocerciasis elimination for the  $<0.1\%$  serological threshold in children aged  $<10$  years is low [10]. Recent modelling work has suggested that a higher threshold of 2% may be safe for stopping MDA and that children aged 5–14 years may be more informative [28]. Yet, considerable uncertainty remains on both the technical threshold for elimination—which is confounded by limited understanding of *O. volvulus* transmission dynamics and population biology at low transmission levels [29]—and whether a particular threshold can be measured using current diagnostic tools [30], particularly RDTs [21,22]. The WHO currently recommends Ov16 ELISA serology, but different ELISA protocols vary in performance characteristics, and laboratory capacity in Africa must be strengthened [31,32]. The development and manufacture of standardized and quality-assured ELISA kits with sensitivity/specificity compatible with measuring (revised) serological thresholds is a priority.

Inspection of all-age serological profiles in the previously hyperendemic villages of Kantila, Nioumala and Galé analysed together provides an overview of historical exposure trends in

Bakoye. Seroprevalence was very low in the  $\leq 14$ -year olds, with upper 95% confidence limits less than 2% in 3–6, 7–10 and 11–14 (Figure 4), suggesting pronounced transmission suppression. Despite the majority of young adults in the 15–19 and 20–24 age groups having lived their lives under MDA with ivermectin, the Ov16 seroprevalence of between approximately 3% and 5% indicates some exposure to *O. volvulus*, probably before the interruption of transmission (i.e. not necessarily indicative of current transmission). From 15–19, Ov16 seroprevalence increases slowly with age, only reaching 16% in those aged  $\geq 40$  years. These individuals would have been  $\geq 15$ –20 years old when ivermectin distribution began and, under intense pre-treatment transmission, their age-specific mf prevalence would already have reached  $>60\%$  [33]. These results are consistent with those of [34], indicating that Ov16 seropositivity likely declines over time after prolonged treatment (although mortality rates in these populations would have also to be considered).

The all-age seroprevalence profiles for Wb123 also increased somewhat with age, reaching 3% in those aged  $\geq 40$  years but remaining below 2% in all those aged  $<40$ . A recent study in Mali found a strong correlation between ICT and Wb123 seropositivity in children aged 6–7 years, suggesting that evaluating IgG4 to Wb123 might in the future (pending further (sero)epidemiological investigations) be useful in stop-MDA decisions or in TAS following MDA cessation, as a measure of recent exposure rather than patent infection [35]. The study in Mali also reported Ov16 seropositivity in children from previously onchocerciasis meso- and hyperendemic communities and none from hypoendemic villages. These findings, together with those presented here and reported in Senegal for children aged  $<10$  years, where the seven seropositive individuals were found in the River Gambia and Fálémé foci [24], indicate that not all Ov16-seropositive results should be dismissed as false positives, as a trend is clearly emerging associating Ov16 seropositivity with pre-MDA endemicity status.

It is hoped that current LF antigenemia and mf prevalence thresholds for EPHP will be sufficient to lead to EOT, albeit empirical evidence for this is limited [23] and LF may persist despite passing TAS [36]. In reality, thresholds indicative of interrupted transmission will vary



with transmission conditions and local vector biting rates [37]. Hence, while mathematical modelling [28,37] can help decision-makers define thresholds based on acceptable levels of risk, elimination will ultimately be demonstrated using robustly-sampled surveillance data. Surveillance will come at a cost that the global health community must recognise and prepare for to sustain the great progress already been made along the path to eliminating onchocerciasis and LF.

## CONCLUSIONS

The antibody seroprevalence against Ov16 and Wb123 antigens among children in the Bakoye and Falémé foci in Mali is very low and consistent with both onchocerciasis and LF having been likely eliminated since stopping MDA in 2016 (pending skin snip PCR-testing of the few Ov16 seropositive children identified, and with the proviso that new studies are needed to confirm the field performance of the bplex RDT). Periodic (including entomological) surveillance should be continued in this region to detect and respond to any early signs of resurgence/re-introduction. This will help to sustain elimination and maintain the Bakoye and Falémé foci as an example of a global health intervention success.

## Notes

**Author contributions.** Conception and design of the study: H. D., Y. I. C., R. C., T. B. N., M. W., M.–G. B. Data collection: H. D., M. S., M. D., S. S. D., S. Y. C., M. B. S., I. L., A. A. D., L. S., M. E. C. Data analysis: H. D., M. W., M.–G. B. Visualization: H. D., D. D., M. W., M.–G.B. Manuscript writing: H. D., M. W., M.–G. B. Read and approved the final version: All authors. H. D., M. W. and M.–G. B. contributed equally.

**Acknowledgments.** The authors wish to thank the study communities, the Programme National de Lutte contre l'Onchocercose du Mali, Programme National d'Elimination de la Filariose Lymphatique du Mali, and the International Center for Excellence in Research (ICER) Mali for their roles in supporting data collection and the logistics of the study. This work is dedicated to the memory of Dr Mamadou Oumar Traoré.

**Disclaimer.** The authors alone are responsible for the views, opinions, assumptions, or any other information expressed in this manuscript, which not necessarily are the views, decisions, or policies of the institutions to which they are affiliated.

**Financial support.** This study was funded in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) [grant no. Z01-AI001063] to the Lymphatic Filariasis Research Unit at the International Center of Excellence in Research (ICER), Mali. H. D. acknowledges financial support from the Islamic Development Bank for a PhD studentship (award no. 600031453) at the University of Antwerp, and from the International Society for Infectious Diseases (ISID)/European Society for Clinical Microbiology and Infectious Diseases (ESCMID) for a joint fellowship at Imperial College London. M. W. and M.–G. B. are supported by the Bill and Melinda Gates Foundation through funding to the NTD Modelling Consortium [grant no. OPP1184344]. M.–G. B. acknowledges joint centre funding (grant No. MR/R015600/1) by the UK Medical Research Council (MRC) and the UK Department for International

Development (DFID) under the MRC/DFID Concordat agreement which is also part of the EDCTP2 programme supported by the European Union.

**Potential conflicts of interest.** T. B. N. is among the patent holders for Ov16 and Wb123 (no longer under patent) and, through the National Institutes of Health, has received licensing/royalty fees for Wb123. All other authors have no potential conflicts.

## References

1. Dembélé M, Bamani S, Dembélé R, *et al.* Implementing preventive chemotherapy through an integrated National Neglected Tropical Disease Control Program in Mali. *PLoS Negl Trop Dis*, **2012**; 6(3): e1574.
2. Akpoboua KL, Hougard JM, Agoua H, Sékétéli A, Quillévéré D. [Importance and role of spreading larvicides on the soil in river beds for the control program against onchocerciasis in west Africa]. *Bull Soc Pathol Exot*, **1994**; 87(4): 278–82 (in French).
3. Boatin BA, Richards FO Jr. Control of onchocerciasis. *Adv Parasitol*, **2006**; 61: 349–94.
4. World Health Organization/African Programme for Onchocerciasis Control. Conceptual and Operational Framework of Onchocerciasis Elimination with Ivermectin Treatment. 2010. Available at: [https://www.who.int/apoc/oncho\\_elimination\\_report\\_english.pdf](https://www.who.int/apoc/oncho_elimination_report_english.pdf). Accessed 31 January 2020.
5. World Health Organization. Accelerating Work to Overcome the Impact of Neglected Tropical Diseases: A Roadmap for Implementation. 2012. Available at: [https://www.who.int/neglected\\_diseases/NTD\\_RoadMap\\_2012\\_Fullversion.pdf](https://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf). Accessed 31 January 2020.
6. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2017. *Wkly Epidemiol Rec*, **2018**; 93(44): 589–601.
7. Diawara L, Traoré MO, Badji A, *et al.* Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. *PLoS Negl Trop Dis*, **2009**; 3(7):e497.
8. Traore MO, Sarr MD, Badji A, *et al.* Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. *PLoS Negl Trop Dis*, **2012**; 6(9): e1825.
9. Kelly-Hope LA, Molyneux DH, Bockarie MJ. Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity? *Parasit Vectors*, **2013**; 6: 39.
10. World Health Organization/Department of Control of Neglected Tropical Diseases. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis. Criteria and procedures (Ukety T, Ed.), 44 pp. 2016. Available at: [https://apps.who.int/iris/bitstream/handle/10665/204180/9789241510011\\_eng.pdf;jsessionid=85ADE0FAAE6368A0802984B4A3810DCF?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/204180/9789241510011_eng.pdf;jsessionid=85ADE0FAAE6368A0802984B4A3810DCF?sequence=1). Accessed 31 January 2020.
11. World Health Organization/Department of Control of Neglected Tropical Diseases. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration. A manual for national elimination programmes (Ichimori K, Ed.), 79pp. 2011. Available at: [https://www.who.int/lymphatic\\_filariasis/resources/9789241501484/en/](https://www.who.int/lymphatic_filariasis/resources/9789241501484/en/). Accessed 31 January 2020.
12. Mali National Health Direction. National Lymphatic Filariasis Elimination Program. 2016 Report. Bamako: Ministère de la Santé et des Affaires Sociales.
13. Walker M, Stolk WA, Dixon MA, *et al.* Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal. *Epidemics*, **2017**; 18: 4–15.

14. Steel C, Golden A, Stevens E, *et al.* Rapid point-of-contact tool for mapping and integrated surveillance of *Wuchereria bancrofti* and *Onchocerca volvulus* infection. Clin Vaccine Immunol, **2015**; 22(8): 896–901.
15. Golden A, Steel C, Yokobe L, *et al.* Extended result reading window in lateral flow tests detecting exposure to *Onchocerca volvulus*: a new technology to improve epidemiological surveillance tools. PLoS One, **2013**; 8(7): e69231.
16. Moreau JP, Prost A, Prod'hon J. [An attempt to normalize the methodology of clinico parasitologic surveys of onchocerciasis in West-Africa (author's transl)]. Med Trop (Mars), **1978**; 38(1): 43–51.
17. Brown LD, Cat TT, DasGupta A. Interval estimation for a proportion. Stat Sci, **2001**; 16 (2): 101–133.
18. Remme J, Ba O, Dadzie KY, Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull World Health Organ, **1986**; 64(5): 667–81.
19. Filipe JAN, Boussinesq M, Renz A, *et al.* Human infection patterns and heterogeneous exposure in river blindness. Proc Natl Acad Sci USA, **2005**; 102(42): 15265–70.
20. SD Bioline onchocerciasis/LF IgG4 Rapid Test. New tools to support disease elimination for both river blindness and elephantiasis. Available at: <https://www.alere.com/en/home/product-details/sd-bioline-onchocerciasis-LF-igg4-rapid-test.html>. Accessed 31 January 2020.
21. Won KY, Sambou S, Barry A, *et al.* Use of antibody tools to provide serologic evidence of elimination of lymphatic filariasis in The Gambia. Am J Trop Med Hyg, **2018**; 98(1): 15–20.
22. World Health Organization. Report of the 1<sup>st</sup> Meeting of the WHO Onchocerciasis Technical Advisory Subgroup. 2017. Available at: <https://apps.who.int/iris/bitstream/handle/10665/273705/WHO-CDS-NTD-PCT-2018.05-eng.pdf>. Accessed 31 January 2020.
23. Unnasch TR, Golden A, Cama V, Cantey PT. Diagnostics for onchocerciasis in the era of elimination. Int Health, **2018**; 10(Suppl 1): i20–i26.
24. Wilson NO, Ly AB, Cama VA, *et al.* Evaluation of lymphatic filariasis and onchocerciasis in three Senegalese districts treated for onchocerciasis with ivermectin. PLoS Negl Trop Dis, **2016**; 10(12): e0005198.
25. Koala L, Nikiéma A, Post RJ, *et al.* Recrudescence of onchocerciasis in the Comoé valley in Southwest Burkina Faso. Acta Trop, **2017**; 166: 96–105.
26. Koala L, Nikiéma AS, Paré AB, *et al.* Entomological assessment of the transmission following recrudescence of onchocerciasis in the Comoé Valley, Burkina Faso. Parasit Vectors, **2019**; 12: 34
27. Cantey PT, Roy SL, Boakye D, *et al.* Transitioning from river blindness control to elimination: steps toward stopping treatment. Int Health, **2018**; 10: i7–i13

28. Coffeng LE, Stolk WA, Golden A, de los Santos T, Domingo GJ, de Vlas SJ. Predictive value of Ov16 antibody prevalence in different subpopulations for elimination of Africa onchocerciasis. *Am J Epidemiol*, **2019**; 188(9): 1723–1732.
29. Hamley JID, Milton P, Walker M, Basáñez MG (2019). Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: implications for elimination and data needs. *PLoS Negl Trop Dis* [in press].
30. Gass KM. Rethinking the serological threshold for onchocerciasis elimination. *PLoS Negl Trop Dis*, **2018**; 12(3): e0006249
31. Ov-16 Meeting Notes | Neglected Tropical Diseases Support Center. Available at: [https://www.ntdsupport.org/sites/default/files/uploads/docs/resources/Ov16%20Technical%20Meeting%20Report\\_May\\_2016.pdf](https://www.ntdsupport.org/sites/default/files/uploads/docs/resources/Ov16%20Technical%20Meeting%20Report_May_2016.pdf). Accessed 31 January 2020.
32. Shott J, Ducker C, Unnasch TR, Mackenzie CD. Establishing quality assured (QA) laboratory support for onchocerciasis elimination in Africa. *Int Health*. **2018**; 10(Suppl 1): i33–i39.
33. Basáñez MG, Boussinesq M. Population biology of human onchocerciasis. *Philos Trans R Soc Lond B Biol Sci*, **1999**; 354(1384): 809–826.
34. Paulin HN, Nshala A, Kalinga A, *et al*. Evaluation of onchocerciasis transmission in Tanzania: Preliminary rapid field results in the Tukuyu Focus, 2015. *Am J Trop Med Hyg*, **2017**; 97(3): 673–676.
35. Dolo H, Coulibaly YI, Dembele B, *et al*. Integrated seroprevalence-based assessment of *Wuchereria bancrofti* and *Onchocerca volvulus* in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test. *PLoS Negl Trop Dis*, **2019**; 13(1): e0007064.
36. Rao RU, Nagodavithana KC, Samarasekera SD, *et al*. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. *PLoS Negl Trop Dis*, **2014**; 8(11): e3281
37. Davis EL, Reimer LJ, Pellis L, Hollingsworth TD. Evaluating the evidence for lymphatic filariasis elimination. *Trends Parasitol*, **2019**; 35(11): 860–869.

**Table 1. Prevalence and Intensity of *Onchocerca volvulus* Microfilariae in the Pre-Ivermectin MDA Period (1985–1988) for 13 Villages in Bakoye, Mali**

Village	Year of survey	Census (% exam)	Positive/ examined	Prevalence (%) <sup>a</sup> (95% CI) <sup>b</sup>	CMFL (mff/ss) <sup>c</sup>	Endemicity level <sup>d</sup>
Fataba-Kouroubala	1988	284 (75.4)	57/ 214	30.6 (24.5–36.7)	3.22	Hypoendemic
Kokounkoutouba	1987	173 (70.5)	28/ 122	30.7 (22.6–38.8)	2.29	Hypoendemic
Baniangafata	1988	208 (75.5)	57/ 157	39.7 (32.1–47.3)	4.36	Hypoendemic
Dianga-Foula	1985	214 (47.2)	48/ 101	43.5 (34.1–53.3)	16.91	Mesoendemic
Fatafing	1987	335 (78.5)	106/ 263	45.5 (39.7–51.7)	6.17	Mesoendemic
Badougou	1988	160 (68.1)	45/ 109	48.4 (39.4–58.0)	4.37	Mesoendemic
Tieourou-Santankoto	1988	340 (86.2)	142/ 293	48.6 (42.8–54.2)	10.20	Mesoendemic
Madila	1987	204 (83.3)	82/ 170	50.1 (42.5–57.5)	8.17	Mesoendemic
Kantila	1985	171 (83.6)	84/ 143	60.1 (52.0–67.9)	17.25	Hyperendemic
Keniefeto	1988	127 (78.0)	51/ 99	62.4 (52.9–71.7)	14.92	Hyperendemic
Nioumala	1985	98 (72.5)	52/ 71	64.9 (53.3–75.2)	33.94	Hyperendemic
Kibi	1988	205 (72.2)	90/ 148	67.5 (59.8–74.8)	21.62	Hyperendemic
Galé	1985	410 (62.9)	173/ 258	70.0 (64.4–75.5)	31.13	Hyperendemic

<sup>a</sup>Standardised prevalence according to OCP reference population [16]; <sup>b</sup>Wilson 95% confidence intervals [17];

<sup>c</sup>CMFL: geometric mean no. of microfilariae (mff) per skin snip (ss) in those aged ≥20 years according to Remme et al. [18]; <sup>d</sup>endemicity levels are defined as: hypoendemic = microfilarial (mf) prevalence <40%; mesoendemic = mf prevalence ≥40% but <60%, and hyperendemic = mf prevalence ≥60% following [13].

**Table 2. Prevalence and Intensity of *Onchocerca volvulus* Microfilariae in the Pre-Ivermectin MDA Period (1986–1990) for 14 Villages in Falémé, Mali**

Village	Year of survey	Census (% exam)	Positive/ examined	Prevalence (%) <sup>a</sup> (95% CI) <sup>b</sup>	CMFL (mff/ss) <sup>c</sup>	Endemicity level <sup>d</sup>
Madina-Mandinga	1990	414 (81.9)	53/ 339	19.9 (15.9–24.3)	2.30	Hypoendemic
Koffing	1987	244 (84.4)	46/ 206	23.3 (18.1–29.5)	1.55	Hypoendemic
Yatia-Berola	1986	217 (81.6)	45/ 177	24.3 (18.6–31.1)	1.29	Hypoendemic
Sakola-Loulo	1986	343 (70.3)	52/ 241	26.6 (21.4–32.5)	1.68	Hypoendemic
Djoulafoundouni	1986	220 (74.6)	43/ 164	30.3 (24.0–37.9)	2.88	Hypoendemic
Koutila	1986	227 (77.1)	55/ 175	33.0 (26.6–40.4)	5.37	Hypoendemic
Djidian-Kenieba	1986	133 (89.5)	48/ 119	40.1 (32.0–49.3)	6.23	Mesoendemic
Moussala	1989	214 (80.4)	65/ 172	42.2 (35.3–49.9)	5.18	Mesoendemic
Sanoukou	1986	164 (82.9)	55/ 136	42.2 (34.0–50.3)	5.18	Mesoendemic
Satadougou-Tintiba	1986	170 (82.4)	55/ 140	43.3 (35.6–51.9)	4.36	Mesoendemic
Sely	1986	231 (71.4)	61/ 165	43.5 (36.3–51.3)	6.20	Mesoendemic
Fadougou	1986	200 (76.0)	65/ 152	47.5 (39.6–55.3)	6.41	Mesoendemic
Kounda-Mahina	1986	271 (80.1)	72/ 217	47.7 (41.4–54.6)	7.02	Mesoendemic
Mankouke	1986	290 (74.8)	125/ 217	56.8 (50.0–63.1)	20.93	Mesoendemic

<sup>a</sup>Standardised prevalence according to OCP reference population [16]; <sup>b</sup>Wilson 95% confidence intervals [17];

<sup>c</sup>CMFL: geometric mean no. of microfilariae (mff) per skin snip (ss) in those aged ≥20 years according to Remme et al. [18]; <sup>d</sup>endemicity levels are as defined in Table 1 [13].



**Table 3. Description of the Study Population Tested with Onchocerciasis/LF IgG4 Rapid Diagnostic Test in Bakoye and Falémé, Mali, 2017–2018**

	<b>Bakoye</b>		<b>Falémé</b>	
	<b>N (% target)</b>	<b>% or [range]</b>	<b>N (% target)</b>	<b>% or [range]</b>
Age group				
Children aged ≤10 years	2,186 (62.3%)		2,270 (82.9%)	
3–6 yr	1,003	45.9	1,415	62.3
7–10 yr	1,183	54.1	855	37.7
Median age (years)	7	[3–10]	6	[3–10]
Male/ Female	1,172/ 1,014	53.6/ 46.4	1,178/ 1,092	51.9/ 48.1
Children aged ≤10 years (Kantila, Nioumala, Galé)	825 (110.4%)		–	–
Persons aged >10 years (Kantila, Nioumala, Galé)	1,042 (82.9%)		–	–
11–14 yr	309 (149.3%)	29.7	–	–
15–19 yr	232 (124.7%)	22.3	–	–
20–24 yr	114 (69.1%)	10.9	–	–
25–29 yr	70 (47.6%)	6.7	–	–
30–39 yr	134 (72.0%)	12.9	–	–
40–49 yr	71 (48.6%)	6.8	–	–
≥50 yr	112 (50.9%)	10.8	–	–
Median age (years)	19	[11–78]	–	–
Male/ Female	496/ 546	47.6/ 52.4	–	–

## Figure legends

### Figure 1. Map of the study area and the location of the study villages in the Kayes region of Mali.

**(A)** Map of Mali showing the location of the Bakoye (solid contour) and Falémé (dashed contour) foci; inset indicates location of Mali within Africa. **(B)** The Bakoye focus is in the Kita cercle, with most the 15 study communities (13 villages and two hamlets) located along the Bakoye river. **(C)** The Falémé focus is in the Kéniéba cercle, with the 16 study communities (15 villages and one hamlet) located along the Falémé river (bordering Senegal). Cercles are the second administrative unit in Mali (the first being regions). Villages (indicated by solid circles) are coloured by their baseline endemicity level: yellow (hypoendemic), orange (mesoendemic) and red (hyperendemic); green circles denote locations for which no baseline data (collected in 1985–1989) were available and therefore their initial endemicity status is unknown.

### Figure 2. Trends in *Onchocerca volvulus* microfilarial infection in Bakoye from 1985 to 2010.

**(A)** Microfilarial (Mf) prevalence. **(B)** Community Microfilarial Load (CMFL), as defined in Table 1 [18]. Error bars for prevalence denote (Wilson score interval) 95% CIs [17]. The baseline data correspond to 1985–1989. In 1989 annual ivermectin MDA started with an initial coverage of 59–62% which improved to 73–83% in 1998–2006 [13]. From 1992 onwards, all first-line villages were treated [7].

### Figure 3. Trends in *Onchocerca volvulus* microfilarial infection in Falémé from 1986 to 2010.

**(A)** Microfilarial (Mf) prevalence. **(B)** Community Microfilarial Load (CMFL), as defined in Table 1 [18]. Error bars for prevalence denote (Wilson score interval) 95% CIs [17]. The baseline data correspond to 1986–1990. In 1990 annual ivermectin MDA started with an initial coverage of 63% which improved to 75–82% in 2000–2006. From 1991 onwards all first-line villages were treated [7].

**Figure 4. Age-specific Ov16 and Wb123 seroprevalence profiles in the villages of Kantila, Nioumala and Galé combined.** Ov16 (white bars) and Wb123 (grey bars) seropositivity by age group with 95% (Wilson score) confidence intervals.

## Supplementary Material

### Supplementary Methods:

Detailed Description of the Study Sites

Temporal Trends of Onchocerciasis Under Mass Drug Administration

**Table S1.** Ov16 and Wb123 IgG4 Seroprevalence by Village in 3–10-year Old Children in Bakoye, Mali, 2017–2018.

**Table S2.** Ov16 and Wb123 IgG4 Seroprevalence by Village in 3–10-year Old Children in Falémé, Mali, 2017–2018.

**Table S3.** Ov16 and Wb123 IgG4 Seroprevalence by Age Group in Three Bakoye Villages Historically Hyperendemic for Onchocerciasis, Mali, 2017–2018.

**Figure S1.** Age-specific Ov16 Seroprevalence in Three Historically Hyperendemic Villages of the Bakoye Focus, Mali, and Three River Basins in the Kédougou Region, Senegal.

Figure 1




Figure 2




Figure 3




Figure 4

